Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pricing Strategies

Set Alert for Pricing Strategies

US Supreme Court Reignites Claims Government Overcharged Millions For Generics

In a case that could have significant ramifications for the scope of the US False Claims Act, the US Supreme Court has agreed to remand for further proceedings allegations that supermarket and pharmacy chains defrauded the government via low-cost drug programs.

Legal Issues Reimbursement

Coherus Plots ‘Lowest Price Adalimumab’ With Huge Discount, Ties Up With Mark Cuban

Coherus BioSciences had teased a “compelling value proposition” for its Yusimry (adalimumab-aqvh) biosimilar to AbbVie’s Humira blockbuster and it has delivered, with a pair of pricing strategies include one though an alliance with self-labelled “disruptor” Mark Cuban.

Biosimilars Pricing Strategies

Ivabradine Prices Rise High Among Recent UK Launches In April

Ivabradine stood out among recently-launched UK generics with an average price rise of more than a third in April, according to the latest figures from market researcher WaveData.

Market Intelligence Pricing Strategies

Samsung Bioepis Biosimilars Report Sees Lower Price Boosting Uptake

Samsung Bioepis has published the first in a planned series of reports on the US biosimilars market, including insights into pricing, uptake and market share for various biosimilars.

Biosimilars Market Intelligence

PBM Vertical Integration Impact Under The Microscope At Senate Hearing

A US Senate Finance Committee has heard divided opinions on the impact of vertical integration among pharmacy benefit managers, with one witness maintaining it may have positive competitive consequences while another condemned the practice outright.

Pricing Debate Companies

UK Generics Body Opens Rift With Government And Originators Over Rebate Scheme

By launching a bid for judicial review of its exclusion from UK negotiations over the VPAS rebate scheme, the BGMA has thrust itself into conflict with the country’s government as well as local brand industry association the ABPI.

Legal Issues United Kingdom

PBM Impact On Off-Patent Industry Condemned At Senate Hearing

Witnesses at a US Senate Finance Committee Hearing have condemned the impact the “perverse” practices of pharmacy benefit managers have on off-patent drugs, often placing them on non-preferred tiers so that patients must use more expensive, branded medication.

Reimbursement Policy

Express Scripts Unveils New Co-Pay Cap For Generics Amid PBM Scrutiny

Cigna’s PBM, Express Scripts, is looking to “further align incentives across the pharmaceutical supply chain, consumers, and clients,” with a trio of new products available starting this summer.

Reimbursement Pricing Debate

Perindopril And Pramipexole Prices Peak In March

Two products featured highly among the fastest-rising UK generics prices in March, but for different reasons.

Market Intelligence Generic Drugs
See All